Eli Lilly Watchlist

tz-plus logo Eli Lilly – Millions of New Patients in Sight! Zepbound Shows Strong Study Results in Adolescents

A. Zehetner
Reading Time: 3 minutes

Zepbound reduced BMI in adolescents by an average of 21.4% in a study model. An additional million-dollar market is approaching. Foundayo convinces in a new survey with its easy intake. The active ingredient recently received approval in China. Under Eloralintide, 74% reported less cravings. New active ingredients are broadening Lilly's pipeline. Eli Lilly (LLY) will present new data on Zepbound, Foundayo, and Eloralintide at the Obesity Congress ObesityWeek from November 14 to 17. The results could open up new patient groups and treatment...

Read this article now with a free account.

Your benefits:

  • Every month, you can read 5 articles from the premium section for free.
  • Monthly 2 trial issues of the Trader newspaper for free.
  • Create a personal watchlist with an overview of news about your stock.
Trader Times
Free account
Here we go!
Image 1Image 2Image 3

Already registered? Log In